Valneva renews its sales agreement in connection with its existing at-the-market (atm) program

Saint-herblain (france), march 26, 2025 – valneva se (nasdaq: valn; euronext paris: vla) (“valneva” or the “company”), a specialty vaccine company, today announces that it has filed a prospectus supplement as part of the renewal of its registration statement on form f-3, filed on march 25, 2025 with the u.s. securities and exchange commission (“sec”) relating to its existing at-the-market offering facility (the “atm program”), which was originally entered into in august 2022 and has not been utilized to-date.
VALN Ratings Summary
VALN Quant Ranking